We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

LumiQuick Diagnostics

LumiQuick Diagnostics Inc. develops, manufactures and markets high quality point of care tests and other immunoassay ... read more Featured Products: More products

Download Mobile App





LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021

LumiQuick Diagnostics, Inc. More...

(Santa Clara, CA, USA) highlighted its newly-launched point-of-care lateral flow assays and ELISA kits at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The event provided an opportunity to connect with global leaders in laboratory medicine, and to discover cutting edge technology and vital research in the field. LumiQuick develops and manufactures extensive product lines that cover point-of-care lateral flow assays, ELISA kits, and other platforms. At AACC 2021, the company highlighted some of its newly-launched products such as the QuickProfile Quantitative Vitamin D rapid test, QuickProfile Zika IgG/IgM antibody rapid test, QuickProfile Chikungunya IgG/IgM antibody rapid test, and Quicknostics Vitamin D ELISA test.

LumiQuick also demonstrated its COVID-19 testing solutions including the QuickProfile 2019-nCoV IgG/IgM Combo Test Card which is an immunochromatography based one step in vitro test. It is designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV, SARS-CoV-2) in human serum, plasma, or whole blood. Rapid 2019-nCoV IgG/IgM Combo Test Card is a supplemental rapid screening tool for symptomatic or asymptomatic carriers of the virus. Also on display was the company’s QuickProfile COVID-19 Antigen Test which is a rapid in vitro immunochromatographic assay for the qualitative detection of SARS-CoV-2 virus antigen present in human nasopharynx.

Related Links:
LumiQuick Diagnostics, Inc. 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.